血清学标志物在肝硬化门静脉高压无创评估中的应用

肖鹏; 张亚南; 巴桃桃; 丁梦梦; 高沿航

doi:10.3969/j.issn.1001-5256.2019.09.042

血清学标志物在肝硬化门静脉高压无创评估中的应用

DOI: 10.3969/j.issn.1001-5256.2019.09.042

吉林大学第一医院肝胆胰内科

基金项目:

“艾滋病和病毒性肝炎等重大传染病防治”国家科技重大专项(2017ZX10202202,2018ZX10302206)；国家重点研发计划“精准医学研究”专项(2017YFC0908103)；吉林省自然科学基金(20160101097JC)；吉林大学高层次创新团队建设项目(2017TD-08)；中央高校基本科研业务费专项资金；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1194
- HTML全文浏览量: 55
- PDF下载量: 355
- 被引次数: 0
出版历程
- 收稿日期: 2019-04-23
- 出版日期: 2019-09-20

Application of serological markers in noninvasive assessment of cirrhotic portal hypertension

Department of Hepatobiliary and Pancreatic Medicine, The First Hospital of Jilin University

Research funding:

摘要

摘要: 门静脉高压最常见的病因为各种原因所致的肝硬化,门静脉压力达到一定程度,将出现脾大、腹水、肝性脑病及食管静脉曲张破裂出血等严重临床并发症,危及患者生命,因此评估门静脉高压对代偿期肝硬化患者的诊断及失代偿期肝硬化患者的治疗和预后至关重要。由于评估门静脉高压的"金标准"肝静脉压力梯度有创、昂贵,门静脉高压无创评估成为当前研究热点。利用血清学标志物无创评估门静脉高压具有简单、易行、可重复的优点,评估门静脉高压的血清学标志物日益受到关注。随着对肝硬化门静脉高压发病机制认识的深入,血清学标志物的研究日益增多,主要包括促炎细胞因子、细胞外基质成分及其循环降解产物等。总结及评述了血清学标志物在门静脉高压无创评估中的进展,以期对临床更早期、更便捷诊断门静脉高压提供帮助。
- 肝硬化 /
- 高血压,门静脉 /
- 生物标记
Abstract: The most common cause of portal hypertension is liver cirrhosis due to various reasons. When portal venous pressure reaches a certain level, serious clinical complications can endanger patient's life, such as splenomegaly, ascites, hepatic encephalopathy, and esophageal variceal bleeding. Therefore, diagnosis and evaluation of portal hypertension is crucial for the diagnosis of patients with compensated cirrhosis and the treatment and prognosis of patients with decompensated cirrhosis. As the gold standard for the evaluation of portal hypertension, hepatic venous pressure gradient is invasive and highly expensive, and thus noninvasive evaluation of portal hypertension has become a research hotspot in recent years. Noninvasive evaluation of portal hypertension based on serological markers is simple, easy, and reproducible, and such serological markers have attracted more and more attention. With in-depth studies on the pathogenesis of cirrhotic portal hypertension, there is an increasing number of studies on serological markers, mainly including pro-inflammatory cytokines, extracellular matrix components, and their cyclic degradation products. This article summarizes and elaborates on the research advances in the role of serological markers in noninvasive assessment of portal hypertension, in order to provide help for early and convenient diagnosis of portal hypertension.
- liver cirrhosis /
- hypertension, portal /
- biomarkers

HTML全文

参考文献(30)

[1] Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Endoscopy, Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32 (2) :203-219. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J].临床肝胆病杂志, 2016, 32 (2) :203-219.

[2] MORIYASU F, NISHIDA O, BAN N, et al. Measurement of portal vascular resistance in patients with portal hypertension[J]. Gastroenterology, 1986, 90 (3) :710-717.

[3] LI H. Prevention and treatment of portal hypertension complicated with hemorrhagein patients with liver cirrhosis through new knowledge on its pathogenesis[J]. Chin J Gastroenterol, 2015, 20 (11) :641-643. (in Chinese) 李海.掌握发病新机制, 有效防治肝硬化门静脉高压出血[J].胃肠病学, 2015, 20 (11) :641-643.

[4] BENOIT JN, WOMACK WA, HERNANDEZ L, et al.“Forward”and“backward”flow mechanisms of portal hypertension. Relative contributions in the rat model of portal vein stenosis[J].Gastroenterology, 1985, 89 (5) :1092-1096.

[5] QIN N, YANG F, LI A, et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature, 2014, 513 (7516) :59-64.

[6] MANDORFER M, SCHWABL P, PATERNOSTRO R, et al. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity[J]. Aliment Pharmacol Ther, 2018, 47 (7) :980-988.

[7] TANG SH, QIN JP, JIANG MD, et al. The agreement and clinical value of hepatic vein pressure gradient and portal vein pressure in patients with portal hypertension[J]. Chin J Hepatol, 2015, 23 (5) :354-357. (in Chinese) 汤善宏, 秦建平, 蒋明德, 等.门静脉高压患者肝静脉压力梯度与门静脉压相关性及其临床价值[J].中华肝脏病杂志, 2015, 23 (5) :354-357.

[8] Chinese Portal Hypertension Diagnosis and Monitoring Study Group; Minimally Invasive Intervention Collaborative Group, Chinese Society of Gastroenterology; Emergency Intervention Committee, Chinese College of Interventionalists, et al. Consensus on clinical application of hepatic venous pressure gradient in China (2018 edition) [J]. Chin J Dig Surg, 2018, 17 (11) :1059-1070. (in Chinese) 中国门静脉高压诊断与监测研究组 (CHESS) , 中华医学会消化病学分会微创介入协作组, 中国医师协会介入医师分会急诊介入专业委员会, 等.中国肝静脉压力梯度临床应用专家共识 (2018版) [J].中华消化外科杂志, 2018, 17 (11) :1059-1070.

[9] BUCK M, GARCIA-TSAO G, GROSZMANN RJ, et al. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients[J]. Hepatology, 2014, 59 (3) :1052-1059.

[10] KARIM AF, EURELINGS LEM, BANSIE RD, et al. Soluble interleukin-2 receptor:A potential marker for monitoring disease activity in IgG4-related disease[J]. Mediators Inflamm, 2018, 2018:6103064.

[11] KOMIYA I, TOMOYOSE T, OUCHI G, et al. Low level of serum HDL-cholesterol with increased s IL-2R predicts a poor clinical outcome for patients with malignant lymphoma and adult T-cell leukemialymphoma[J]. Cytokine, 2018, 105:57-62.

[12] HUANG XQ, ZHANG R, JIANG YY, et al. Clinical evaluation of the correlation between serum soluble cytokines and hepatic venous pressure gradient[J]. Chin J Gastroenterol Hepatol, 2018, 27 (9) :991-994. (in Chinese) 黄晓铨, 张瑞, 蒋颖溢, 等.血清炎症标志物与肝静脉压力梯度相关性的临床评价[J].胃肠病学和肝病学杂志, 2018, 27 (9) :991-994.

[13] KAZANKOV K, BARRERA F, MOLLER HJ, et al. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C[J].Hepatology, 2014, 60 (2) :521-530.

[14] GRONBAEK H, SANDAHL TD, MORTENSEN C, et al. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis[J]. Aliment Pharmacol Ther, 2012, 36 (2) :173-180.

[15] SANDAHL TD, MCGRAIL R, MLLER HJ et. al. The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2016, 43 (11) :1222-1231.

[16] RAINER F, HORVATH A, SANDAHL TD, et al. Soluble CD163and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation[J]. Aliment Pharmacol Ther, 2017, 47 (5) :657-664.

[17] MANDORFER M, SCHWABL P, PATERNOSTRO R, et al. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity[J]. Aliment Pharmacol Ther, 2018, 47 (7) :980-988.

[18] YILMAZ VT, DINCER D, AVCI AB, et al. Significant association between serum levels of Von Willebrand Factor (v WF) antigen with stages of cirrhosis[J]. Eurasian J Med, 2015, 47 (1) :21-25.

[19] IBRAHIM EH, MARZOUK SA, ZEID AE, et al. Role of the von Willebrand factor and the VITRO score as predictors for variceal bleeding in patients with hepatitis C-related cirrhosis[J]. Hepatology, 2019, 31 (2) :241-247.

[20] WERESZCZYNKA-SIEMIATKOWSKA U, SWIDNICKA-SIERGIEJKO A, SIEMIATKOWSKI A, et al. Endothelin 1 and transforming growth factor-β1 correlate with liver function and portal pressure in cirrhotic patients[J]. Cytokine, 2015, 76 (2) :144-151.

[21] AGNIESZKA SS, URSZULA WS, ANDRZEJ S, et al. The imbalance of peripheral interleukin-18 and transforming growth factor-β1 levels in patients with cirrhosis and esophageal varices[J]. Cytokine, 2019, 113:440-445.

[22] JANSEN C, LEEMING DJ, MANDORFER M, et al. PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension[J]. PLo S One, 2014, 9 (9) :e108544.

[23] LEEMING DJ, KARSDAL MA, BYRJALSEN I, et al. Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension[J]. Aliment Pharmacol Ther, 2013, 38 (9) :1086-1096.

[24] LEEMING DJ, VEIDAL SS, KARSDAL MA, et al. Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis[J]. Scand J Gastroenterol, 2015, 50 (5) :584-592.

[25] BUSK TM, BENDTSEN F, NIELSEN HJ, et. al. TIMP-1 in patients with cirrhosis:Relation to liver dysfunction, portal hypertension, and hemodynamic changes[J]. Scand J Gastroenterol, 2014, 49 (9) :1103-1110.

[26] FENG H, GONG L, TANG XJ, et al. Predictive value of noninvasive serological liver fibrosis scoring system for esophageal and gastric varices in cirrhosis[J]. Chin J Dig, 2017, 37 (8) :554-556. (in Chinese) 凤辉, 龚镭, 唐学军, 等.无创血清学肝纤维化评分系统对肝硬化食管胃底静脉曲张的预测价值[J].中华消化杂志, 2017, 37 (8) :554-556.

[27] VERMA V, SARIN SK, SHARMA P, et al. Correlation of aspartate aminotransferase/platelet ratio index with hepatic venous pressure gradient in cirrhosis[J]. United European Gastroenterol J, 2014, 2 (3) :226-231.

[28] PROCOPET B, CRISTEA VM, ROBIC MA, et al. Serum tests, liver stiffness and artificial neural networks for diagnosing cirrhosis and portal hypertension[J]. Dig Liver Dis, 2015, 47 (5) :411-416.

[29] BRUHA R, JACHYMOVA M, PETRTYl J, et al. Osteopontin:A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis[J]. World J Gastroenterol, 2016, 22 (12) :3441-3450.

[30] PIND ML, BENDTSEN F, KALLEMOSE T, et. al. Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis[J]. Gastroenterol Hepatol, 2016, 28 (8) :948-954.

施引文献

资源附件(0)

访问统计